Australian cell therapy company Chimeric Therapeutics (ASX:CHM) has announced that CHM CDH17 has advanced to dose level 2.
The company said the dose escalation follows no safety concerns or off-target effects observed at dose level 1. It said that dose level 2 has commenced. One patient administered at dose level 2 has achieved tumour shrinkage of 12 per cent at the first scan post the dose.
"Importantly, there has been no evidence of off-target effects or gastrointestinal toxicity and as such the safety window has been passed, we are now cleared to treat more patients at dose level 2," said the company.
“This is great progress, we can see the cells are hard at work; looking forward to more data,” said Chimeric CEO Dr Rebecca McQualter.
The trial is a two-stage study designed to determine a recommended Phase 2 dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumours.